Abstract:Ednan K Bajwa, 1 Dawn Cislak, 1 Amit Kumar, 1 Dan Li, 1 Eric J Messina, 1 Tom Reynders, 2 Jean-François Denef, 2 Vasile Corcea, 3 Ketan P Buch, 4 Eseng Lai, 1 S Aubrey Stoch 1 1 MRL, Merck & Co., Inc., Rahway, NJ, USA; 2 Translational Medicine, MSD Belgium, Brussels, Belgium; 3 PMSI Republican Clinical Hospital "T. Mosneaga", ARENSIA EM Unit, Chisinau, Republic of Moldova; 4 Department of Internal Medicine, Pulmonary and Critical Care Medicine, Lexington VA Healthcare, Lexington, KY, USA Correspondence: Ednan K Bajwa, Translational Medicine, Merck Research Laboratories Massachusetts LLC, 33 Avenue Louis Pasteur, MAILSTOP BMB-3-420, Boston, MA, 02115-5727, USA, Tel +1 617 992-3470, Email Purpose: This phase 1 study (NCT04370873) evaluated safety and pharmacokinetics/pharmacodynamics (PK/PD) of MK-5475 in participants with pulmonary hypertension associated with COPD (PH-COPD). Methods: Eligible participants were 40– 80 years old with COPD (FEV 1 /FVC < 0.7; FEV 1 > 30% predicted) and PH (mean pulmonary arterial pressure ≥ 25 mmHg). Participants were randomized 2:1 to MK-5475 or placebo via dry-powder inhaler once daily for 7 days in Part 1 (360 μg) or 28 days in Part 2 (380 μg). Safety was assessed by adverse events (AEs) and arterial blood oxygenation. Part-2 participants had pulmonary vascular resistance (PVR; primary PD endpoint) and pulmonary blood volume (PBV; secondary PD endpoint) measured at baseline and Day 28. A non-informative prior was used to calculate posterior probability (PP) that the between-group difference (MK-5475 – placebo) in mean percent reduction from baseline in PVR was less than − 15%. Results: Nine participants were randomized in Part 1, and 14 participants in Part 2. Median age of participants (86.4% male) was 68.5 years (41– 77 years); 95.5% had moderate-to-severe COPD. Incidences of AEs were comparable between MK-5475 and placebo: overall (5/14 [36%] versus 5/8 [63%]), drug-related (1/14 [7%] versus 2/8 [25%]), and serious (1/14 [7%] versus 1/8 [13%]). MK-5475 caused no meaningful changes in arterial blood oxygenation or PBV. MK-5475 versus placebo led to numerical improvements from baseline in PVR (− 21.2% [95% CI: − 35.4, − 7.0] versus − 5.4% [95% CI: − 83.7, 72.9]), with between-group difference in PVR less than − 15% and calculated PP of 51%. Conclusion: The favorable safety profile and numerical reductions in PVR observed support further clinical development of inhaled MK-5475 for PH-COPD treatment. Keywords: pulmonary hypertension, chronic obstructive pulmonary disease, MK-5475, soluble guanylate cyclase stimulator, dry powder inhaler, pulmonary vascular resistance Chronic obstructive pulmonary disease (COPD) is an often-debilitating lung disease that can be further complicated by pulmonary hypertension (PH). 1,2 PH associated with COPD (PH-COPD) leads to greater morbidity, mortality, and utilization of healthcare resources than does COPD associated with normal pulmonary pressures. 3 The mechanisms by which PH arises in the context of COPD are unclear, but the associated pulmonary vascular remodeling is like that seen with other PH manifestations, 3–9 such as pulmonary arterial hypertension (PAH), including thickening of the pulmonary arterial walls, obliteration of the vascular lumen, and elevation of mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR). PH-COPD (World Health Organization [WHO] Group 3 PH) lacks any approved therapeutic treatment. 10,11 Despite the pathophysiological similarities with PAH (WHO Group 1 PH), the vasodilators used for the treatment of PAH 12 have not consistently shown efficacy against PH-COPD. 5,13–16 Vasodilators like phosphodiesterase type-5 inhibitors (PDE5i) and the soluble guanylate cyclase (sGC) stimulator, riociguat, act on the nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway to increase the production of cGMP, which potentiates tissue relaxation in vascular smooth muscle cells. 17 Although nonclinical data suggest that targeting the NO-cGMP pathway with PDE5i and sGC stimulators may positively affect PH-COPD in animals, 18,19 studies of PDE5i and riociguat in patients with PH-COPD have shown mixed results. 20,21 Another concern with coopting PAH treatment strategies for PH-COPD treatment is the potential for systemic side effects of vasodilation, particularly with combination therapy regimens. Systemic vasodilators may inhibit hypoxic pulmonary vasoconstriction in poorly ventilated regions of lung tissue in patients with PH-COPD, leading to a v -Abstract Truncated-

ATMOS, a Proof-of-Concept trial of inhaled mosliciguat in untreated PAH or CTEPH

Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension.

MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study

Phase 1 Study of MK-5475, an Inhaled Soluble Guanylate Cyclase Stimulator, in Participants with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease

Pulmonary Hypertension: Intensification and Personalization of Combination Rx (PHoenix): A phase IV randomized trial for the evaluation of dose‐response and clinical efficacy of riociguat and selexipag using implanted technologies

Inhaled soluble guanylate cyclase stimulator for the treatment of pulmonary arterial hypertension: struggling to breathe easy

Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors

Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a soluble guanylate cyclase stimulator, HEC95468, in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial

Abstract 11891: Pulmonary Delivery of Novel BEPI/NO-Microparticle for Treatment of Pulmonary Arterial Hypertension

Exploring PI3Kδ Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled Trials

A randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of Eisenmenger syndrome

CS1, a controlled‐release formulation of valproic acid, for the treatment of patients with pulmonary arterial hypertension: Rationale and design of a Phase 2 clinical trial

Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension

Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial

Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1)

Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure

Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study

StratosPHere 2: study protocol for a response-adaptive randomised placebo-controlled phase II trial to evaluate hydroxychloroquine and phenylbutyrate in pulmonary arterial hypertension caused by mutations in BMPR2